Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Double Point Ventures is a venture capital firm founded by Dr. Campbell Murray and Dr. Daniel Yadegar. Established in the United States, the firm focuses on investing in early-stage and transformative companies within the healthcare sector. The founders bring extensive experience in clinical medicine and venture capital, which informs their investment strategy.
Currently, Double Point Ventures manages a concentrated portfolio of six companies, emphasizing high-conviction investments. The firm operates primarily in Boston, Massachusetts, and is known for its commitment to backing pioneering innovations that have the potential to significantly improve patient care. Notable milestones include the acquisition of Lumos Pharma in December 2024 for $27.65 million, showcasing the firm's capability in take-private transactions.
Double Point Ventures invests across various sectors within healthcare, including therapeutics, diagnostics, medical devices, and digital health. Their investment strategy encompasses early-stage companies that are developing small molecules, biologics, gene and cell therapies, and precision medicine. The firm also targets early-revenue and innovative platforms in diagnostics and devices, as well as healthcare services aimed at improving patient care.
The firm emphasizes strategic partnerships and operational guidance to enhance the potential for success among its portfolio companies. Double Point Ventures seeks to partner with companies that demonstrate the ability to fundamentally change patient care through their innovations. This focus on transformative healthcare solutions positions the firm as a key player in the early-stage investment landscape.
Double Point Ventures maintains a concentrated portfolio of six companies, each representing significant potential within the healthcare sector. Notable portfolio companies include:
These companies exemplify Double Point Ventures' commitment to investing in pioneering healthcare innovations that can significantly enhance patient outcomes.
Dr. Campbell Murray, MD, MPP, MBA - Co-Founder & Managing Partner. Dr. Murray has over 20 years of experience in venture capital and biotech leadership, with a strong background in clinical medicine.
Dr. Daniel Yadegar, MD - Co-Founder & Managing Partner. Dr. Yadegar focuses on life extension, regenerative medicine, and has expertise in cardiovascular and reproductive medicine.
Chris Uzpen - Chief Legal Counsel & Fund Advisor. Chris provides legal guidance and strategic advice to the firm, leveraging his experience in venture capital.
To pitch to Double Point Ventures, founders should visit their website at doublepointventures.com. The pitch deck should include a clear overview of the business model, market potential, and team qualifications. Founders are encouraged to provide detailed information about their innovation and its impact on patient care. Response times may vary, but founders should expect a thorough review process.
In December 2024, Double Point Ventures successfully acquired Lumos Pharma in a $27.65 million tender offer, marking a significant milestone for the firm. This acquisition highlights their capability in take-private transactions and their commitment to supporting transformative healthcare innovations.
As of late 2025, Double Point Ventures continues to manage a concentrated portfolio of six companies, focusing on high-conviction investments in the healthcare sector.
What are Double Point Ventures' investment criteria?
The firm focuses on early-stage investments in healthcare companies, particularly those involved in therapeutics, diagnostics, medical devices, and digital health. They seek companies that demonstrate the potential to fundamentally change patient care.
How can founders apply or pitch to Double Point Ventures?
Founders can submit their pitches through the firm's website at doublepointventures.com. It is advisable to include detailed information about the company's innovation, market potential, and team background in the pitch deck.
What makes Double Point Ventures different from other VC firms?
Double Point Ventures is distinguished by its concentrated portfolio strategy, focusing on high-conviction investments in transformative healthcare innovations. The firm also has a unique capability for take-private transactions, as demonstrated by the acquisition of Lumos Pharma.
What is the geographic scope of Double Point Ventures?
The firm primarily invests in companies based in the United States, focusing on early-stage healthcare innovations.
What kind of post-investment involvement does Double Point Ventures have?
Double Point Ventures provides operational guidance and strategic partnerships to its portfolio companies, enhancing their potential for success in the healthcare market. This long-term commitment supports the growth and development of the companies they invest in.
What is the typical check size for investments?
While specific check sizes are not disclosed, Double Point Ventures operates in the pre-seed, seed, and seed-plus stages, indicating a focus on early-stage funding rounds.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.